Madrigal Shatters Street Expectations With $62m In Q3 Rezdiffra Sales

 
• By Joseph Haas
  
Madrigal's Rezdiffra is off to a promising launch in NASH (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Therapy Areas